Bamlanivimab and etesevimab for COVID-19: Withdrawal from the rolling review process


EMA has ended the rolling review of bamlanivimab and etesevimab, two antibodies developed by Eli Lilly Netherlands BV, after the company informed the Agency that it was withdrawing from the process.

The rolling review started on 11 March 2021; the company withdrew on 29 October 2021. 

Key facts

Bamlanivimab and etesevimab for COVID-19
Product number
Active substance
  • Bamlanivimab
  • Etesevimab
Date of withdrawal
Company making the application
Eli Lilly Nederland B.V.
Withdrawal type
Initial authorisation

Related information on withdrawals

A question-and-answer (Q&A) document provides a summary of the CHMP's evaluation of the medicine at the time of the withdrawal of the application, and includes a link to the company's formal withdrawal letter.

An assessment report is published when the application is withdrawn after the first stage of the CHMP's evaluation is completed ('day 120').

How useful was this page?

Add your rating
1 rating